Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. - Liu, J. F.; Moore, K. N.; Birrer, M. J.; Berlin, S.; Matulonis, U. A.; Infante, J. R.; Wolpin, B.; Poon, K. A.; Firestein, R.; Xu, J.; Kahn, R.; Wang, Y.; et al. (Annals of Oncology, 2016)